This policy brief provides antiretroviral therapy programme managers, implementing partners, procurement and supply chain managers, and other relevant stakeholders with key points to consider before and during the introduction of the new dosage form of ritonavir-boosted lopinavir (LPV/r) oral pellets.

Topic Tags
Document Type Tags